Drug Profile
Peretinoin - Kowa
Alternative Names: K-333; NIK-333Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Kowa Pharmaceutical
- Class Antineoplastics; Diterpenes; Retinoids; Skin disorder therapies; Small molecules
- Mechanism of Action Apoptosis stimulants; Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Liver cancer
Most Recent Events
- 28 Dec 2022 Discontinued - Phase-I for Liver cancer (Recurrent) in European Union (PO)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Liver-cancer(Recurrent) in European Union (PO, Tablet)
- 17 Apr 2018 Phase I development for liver cancer (Recurrent) is ongoing in European Union (Kowa pipeline, April 2018)